← Back to Screener
Zevra Therapeutics, Inc. Common Stock (ZVRA)
Price$10.78
Favorite Metrics
Price vs S&P 500 (26W)-6.05%
Price vs S&P 500 (4W)6.30%
Market Capitalization$601.51M
P/E Ratio (Annual)7.23x
All Metrics
Book Value / Share (Quarterly)$2.72
P/TBV (Annual)3.40x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)116.72%
Cash Flow / Share (Quarterly)$-0.04
Price vs S&P 500 (YTD)16.38%
Gross Margin (TTM)96.37%
Net Profit Margin (TTM)78.17%
EPS (TTM)$1.47
10-Day Avg Trading Volume0.73M
EPS Excl Extra (TTM)$1.47
Revenue Growth (5Y)51.61%
EPS (Annual)$1.45
ROI (Annual)38.43%
Gross Margin (Annual)96.37%
Net Profit Margin (5Y Avg)-192.68%
Cash / Share (Quarterly)$3.36
P/E Basic Excl Extra (TTM)7.23x
Revenue Growth QoQ (YoY)183.36%
P/E Normalized (Annual)7.23x
ROA (Last FY)29.23%
Revenue Growth TTM (YoY)350.91%
EBITD / Share (TTM)$1.63
ROE (5Y Avg)-68.35%
Operating Margin (TTM)-59.12%
Cash Flow / Share (Annual)$-0.04
P/B Ratio3.89x
P/B Ratio (Quarterly)3.26x
Net Income / Employee (Annual)$1
EV / Revenue (TTM)5.65x
Net Interest Coverage (TTM)99.27x
ROA (TTM)33.84%
EV / EBITDA (TTM)6.56x
EPS Incl Extra (Annual)$1.45
Current Ratio (Annual)5.68x
Quick Ratio (Quarterly)5.46x
3-Month Avg Trading Volume1.01M
52-Week Price Return50.77%
P/E Incl Extra (TTM)7.23x
Revenue / Employee (TTM)$2
Tangible BV / Share (Quarterly)$2.61
P/S Ratio (Annual)5.65x
Asset Turnover (Annual)0.37x
52-Week High$13.16
Operating Margin (5Y Avg)-208.77%
EPS Excl Extra (Annual)$1.45
CapEx CAGR (5Y)94.50%
26-Week Price Return0.84%
Quick Ratio (Annual)5.46x
13-Week Price Return19.51%
Total Debt / Equity (Annual)0.40x
Current Ratio (Quarterly)5.68x
Enterprise Value$601.034
Revenue / Share Growth (5Y)-11.05%
Asset Turnover (TTM)0.43x
Revenue / Employee (Annual)$2
Pretax Margin (Annual)81.41%
Cash / Share (Annual)$3.36
3-Month Return Std Dev56.64%
Net Income / Employee (TTM)$1
ROE (Last FY)53.82%
Net Interest Coverage (Annual)7.57x
EPS Basic Excl Extra (Annual)$1.45
P/FCF (TTM)62.00x
Receivables Turnover (TTM)6.31x
Total Debt / Equity (Quarterly)0.40x
EPS Incl Extra (TTM)$1.47
Receivables Turnover (Annual)6.49x
ROI (TTM)48.24%
P/S Ratio (TTM)5.65x
Pretax Margin (5Y Avg)-180.49%
Revenue / Share (Annual)$1.86
Tangible BV / Share (Annual)$2.61
Forward P/E6.68x
Price vs S&P 500 (52W)16.14%
P/E Ratio (TTM)7.23x
Year-to-Date Return20.31%
5-Day Price Return10.11%
EPS Normalized (Annual)$1.45
ROA (5Y Avg)-19.83%
Net Profit Margin (Annual)78.17%
Month-to-Date Return15.67%
Cash Flow / Share (TTM)$-1.15
EBITD / Share (Annual)$1.60
Operating Margin (Annual)-59.12%
LT Debt / Equity (Annual)0.40x
ROI (5Y Avg)-31.78%
P/E Excl Extra (TTM)7.23x
LT Debt / Equity (Quarterly)0.40x
EPS Basic Excl Extra (TTM)$1.47
P/TBV (Quarterly)3.40x
P/B Ratio (Annual)3.26x
Inventory Turnover (TTM)2.08x
Pretax Margin (TTM)81.41%
Book Value / Share (Annual)$2.72
Price vs S&P 500 (13W)17.13%
Beta0.93x
P/FCF (Annual)58.17x
Revenue / Share (TTM)$1.81
ROE (TTM)74.63%
52-Week Low$6.85
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.21
4.21
4.21
4.27
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ZVRAZevra Therapeutics, Inc. Common Stock | 5.65x | 350.91% | 96.37% | — | $10.78 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.71 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.93x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Zevra Therapeutics is a biopharmaceutical company focused on developing and commercializing transformational therapies for rare diseases with limited or no existing treatment options. The company employs data-driven strategies to overcome complex drug development challenges and accelerate the delivery of novel therapeutics to underserved patient populations.